How Technology and Analytics Are Helping Big Pharma Improve Patient Engagement in R&D

Posted by Kristyn Feldman on Wed, Nov 01, 2017

Lisa Bance co-wrote this blog post with Kristyn Feldman.

This is the third post in a four-part series examining patient centricity within R&D.

As drug development continues to grow more expensive and complex, and as patients expect to be more involved and empowered throughout the healthcare system, pharmaceutical companies are seeing the value in partnering with patients throughout the R&D process. The journey begins with building an understanding of and empathy for today’s patients, and then uncovering and meeting their needs. The third step is to hone in on how you connect with patients to increase the effectiveness of your communications.


>
Read More

How Biopharma Companies Are Working to Uncover and Meet Patient Needs

Posted by Kristyn Feldman on Wed, Oct 25, 2017

Lisa Bance co-wrote this blog post with Kristyn Feldman.

This is the second post in a four-part series examining patient centricity within R&D.

As pharmaceutical companies aim to make their drug development processes more patient-centric, we’ve noted that a formula for success is starting to emerge, and we’ve packaged that formula into our four pillars of patient centricity in R&D. In our last post, we addressed the first pillar: gaining an understanding of and empathy for patients. In this post, we review the second pillar: uncovering and meeting patients’ needs.


>
Read More

How to Develop a Patient-Centric R&D Process

Posted by Kristyn Feldman on Wed, Oct 18, 2017

Lisa Bance co-wrote this blog post with Kristyn Feldman.

This post is the first in a four-part series examining patient centricity within R&D.

The concept of patient centricity within drug development is far from novel, yet many pharmaceutical companies still struggle to put the patient at the center of their R&D efforts. In a recent article, we wrote about the need for pharmaceutical companies to become true partners in patients’ health. In fact, our research shows that engaging patients from the outset could lead to improved patient recruitment and retention and reduce R&D costs and timelines. Here’s the first step—one of four—that companies can take to start moving toward patient-centric drug development.


>
Read More

Discussing Patient Centricity’s Challenges and Opportunities

Posted by Pratap Khedkar on Wed, Jun 21, 2017

In my last blog post, I used the pharmaceutical industry’s quest for patient centricity as a jumping-off point to discuss how pharma companies need to focus on customer centricity, rethinking their commercial strategies to better address their many stakeholders in the evolving healthcare ecosystem. But since patients’ wellness is the pharmaceutical industry’s reason for being, patient centricity should remain pharma’s North Star. 


>
Read More

Five Observations From the 2017 Fair Pricing Forum

Posted by Ed Schoonveld on Mon, May 15, 2017

In May, I joined various members of governmental organizations, patient organizations and the life sciences industry at the 2017 Fair Pricing Forum, an invitation-only meeting to discuss “fair pricing” for medications in Amsterdam. Organized by the World Health Organization and the Dutch Ministry of Health, the meeting prompted a productive dialogue among stakeholders but also revealed a worrisome gap in the overall perception of the drug pricing discussion. The pharmaceutical industry’s viewpoint was widely underrepresented, with attendance heavily weighted toward governments and activists, and only a small industry delegation.


>
Read More